RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of QURE
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Thursday for uniQure N.V. stock after losing 3.88%
(Updated on Mar 28, 2024)

Sell candidate since Feb 29, 2024 Loss -9.57% PDF

The uniQure N.V. stock price fell by -3.88% on the last day (Thursday, 28th Mar 2024) from $5.41 to $5.20. During the last trading day the stock fluctuated 4.65% from a day low at $5.16 to a day high of $5.40. The price has risen in 6 of the last 10 days and is up by 7.88% over the past 2 weeks. Volume has increased on the last day by 169 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 758 thousand shares were bought and sold for approximately $3.94 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.93% during the next 3 months and, with a 90% probability hold a price between $3.83 and $5.22 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

QURE Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, March 14, 2024, and so far it has risen 7.88%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The uniQure N.V. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $5.28 and $5.54. A break-up above any of these levels will issue buy signals. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for uniQure N.V. stock

uniQure N.V. finds support from accumulated volume at $5.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.240 between high and low, or 4.65%. For the last week, the stock has had daily average volatility of 4.13%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (QURE) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect uniQure N.V. to open at $5.25, and during the day (based on 14 day Average True Range), to move between $4.90 and $5.50, which gives a possible trading interval of +/-$0.299 (+/-5.74%) up or down from last closing price. If uniQure N.V. takes out the full calculated possible swing range there will be an estimated 11.49% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $5.17 (0.58%) than the resistance at $5.59 (7.50%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is uniQure N.V. stock A Buy?

uniQure N.V. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.566 Sell Candidate Unchanged

Predicted Opening Price for uniQure N.V. of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$5.25 ( 1.03%) $5.20

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for QURE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.49 5.64 %
R2 5.40 3.88 %
R1 5.35 2.79 %
Current price: 5.20
Support S1 5.16 -0.737 %
S2 5.11 -1.83 %
S3 5.01 -3.59 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.76 10.77 %
R2 5.75 10.58 %
R1 5.59 7.50 %
Current price 5.20
Support S1 5.17 -0.577%
S2 5.16 -0.769%
S3 4.97 -4.42%

FAQ

What is the symbol for uniQure N.V. Stock and on which exchange is it traded?
The symbol for uniQure N.V. is QURE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell uniQure N.V. Stock?
uniQure N.V. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy uniQure N.V. Stock?
uniQure N.V. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy uniQure N.V. Stock.

What's the current price of uniQure N.V. Stock?
As of the end of day on the 2024-03-28, the price of an uniQure N.V. (QURE) share was $5.20.

What is the 52-week high and low for uniQure N.V. Stock?
The 52-week high for uniQure N.V. Stock is $22.48 and the 52-week low is $4.76.

What is the market capitalization of uniQure N.V. Stock?
As of the 2024-03-28, the market capitalization of uniQure N.V. is 248.759M.

When is the next earnings date for uniQure N.V.?
The upcoming earnings date for uniQure N.V. is May 14, 2024.
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT